Eli Lilly to invest $3bn in China in anticipation of orforglipron approval
Eli Lilly is continuing its global investment drive to ensure it can meet future demand for its highly anticipated oral …
Post
-
-
BioNTech co-founders step down to launch new mRNA venture
The co-founders of BioNTech will leave the company to launch a new mRNA-focused entity, amid mounting losses for the vaccine …
-
UK health authorities join forces to champion foreign infectious disease trials
Health divisions within the UK government and British non-profit organisations have banded together to support infectious disease trials in Africa, …
-
Idorsia and Pharmalink sign agreement to distribute Quviviq
Idorsia has signed an exclusive agreement with Pharmalink Drug Store to distribute and commercialise its Quviviq (daridorexant) insomnia therapy in …
-
FDA approves GSK’s Wellcovorin for cerebral folate deficiency
The US Food and Drug Administration (FDA) has granted its approval for the expanded use of GSK’s Wellcovorin (leucovorin calcium) …
-
FDA approves GSK’s Wellcovorin for cerebral folate deficiency
The US Food and Drug Administration (FDA) has granted its approval for the expanded use of GSK’s Wellcovorin (leucovorin calcium) …
-
Peptides in the pipeline: How companies are overcoming the early-stage challenges
Much larger than traditional small molecule drugs, peptides enable rapid tissue penetration while retaining the selectivity and potency of a …
-
US vaccine manufacturers set to lose as RFK pushes for weaker vaccine mandates
Earlier this year, the Trump Administration, backed by US Health and Human Services Secretary Robert F Kennedy (RFK) Jr, a …
-
FDA homes in on biosimilar accessibility in new draft guidance
The US Food and Drug Administration (FDA) has further updated its regulatory framework around biosimilar medicines in a bid to …
-
Building for decades: Dubai’s long game in life sciences
Editor's note: This feature was reported in part prior to the escalation of hostilities in the Gulf, when Iran launched …
-
Junshi receives China’s NMPA acceptance for toripalimab injection
Junshi Biosciences has received acceptance from China’sNational Medical Products Administration (NMPA) for toripalimab subcutaneous injection (JS001sc) new drug applications (NDAs) …
-
Novo and Hims & Hers become partners to end legal feud
Novo Nordisk and Hims & Hers have come to an agreement that will see the telehealth company sell Novo’s branded …
-
NewcelX and Eledon partner for NCEL-101 programme
NewcelX has signed a collaborative research agreement with Eledon Pharmaceuticals to advance its NCEL-101 programme for type 1 diabetes (T1D). The …
-
GlobalData’s key thoughts from World EPA Congress 2026
GlobalData Healthcare recently attended the World Evidence, Pricing and Access (EPA) congress in Amsterdam on 3-4 March 2026. This conference …
-
GSK sells liver disease drug candidate to Alfasigma for $690m
Alfasigma has agreed to buy the global rights to GSK’s experimental liver disease drug in a deal worth up to …
